AF
ZVRA icon

Amalgamated Financial’s Zevra Therapeutics ZVRA Stock Holding History

Amalgamated Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$21K Buy
+4,181
New +$26.6K ﹤0.01% 2740

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Amalgamated Financial's ZVRA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Zevra Therapeutics (ZVRA) in Q1 2022: 4,181 shares worth $21K. The stake represents ﹤0.01% of the portfolio and ranks #2740 among its holdings.

83 funds tracked by Wall St. Rank hold ZVRA as of Q1 2022.

  • Amalgamated Financial held 4,181 shares of Zevra Therapeutics worth $21K as of Q1 2022.
  • Zevra Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Zevra Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2740 holding.
  • 83 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.